文献速递静脉血栓栓塞慢性静脉疾病

Paget-Schroetter综合征急性上肢深静脉血栓的血管内治疗:三种技术纵向分析

Endovascular treatment of acute upper extremity deep vein thrombosis in Paget-Schroetter syndrome: A longitudinal analysis of three endovascular techniques.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2026-03-23

单中心回顾性纵向研究纳入41例Paget-Schroetter综合征急性上肢深静脉血栓患者,比较计算机辅助真空血栓切除(CAVT)、AngioJet/Zelante导管和导管导向溶栓(CDT)的短期通畅率、并发症及病程。结果显示导管导向治疗安全有效,CAVT无再干预生存率更高(P = .04),单次血栓切除可能减少再干预并提高一期通畅率。

要点

  • 导管导向治疗对Paget-Schroetter综合征安全有效,主要出血事件仅1例。
  • CAVT的无再干预生存率显著高于其他技术(P = .04)。
  • 症状缓解主要发生在2周内,肿胀从98%降至17%,疼痛从60%降至14%。

核心结论

  • 导管导向治疗对Paget-Schroetter综合征所致急性上肢深静脉血栓安全有效。
  • 单次血栓切除(尤其CAVT)可能减少再干预并提高一期通畅率。

研究设计与样本

  • 单中心回顾性纵向研究,纳入2017至2025年苏黎世大学医院41例连续急性Paget-Schroetter综合征患者。
  • 所有患者接受介入血栓切除,使用CAVT、AngioJet/Zelante导管或CDT。
  • 中位年龄34岁,61%为男性,41%为运动员,中位症状持续时间4天。

主要发现

  • 一期通畅率2周为60%(24/40)、3个月为52.6%(20/38)、6个月为54.1%(20/37),组间差异P = .08。
  • 二期通畅率分别为72%、76%、86%。
  • Kaplan-Meier分析显示CAVT后无再干预生存率更高(P = .04)。
  • 症状缓解主要在前2周:肿胀从98%降至17%,疼痛从60%降至14%;发绀6个月内消退,感觉异常从15%轻度增至23%。

关键数值与推荐

  • 血栓切除方式:AngioJet/Zelante占61%,CAVT占17%,CDT占22%。
  • 仅发生1例主要出血事件和1例轻微出血事件。

临床怎么用

  • 对于Paget-Schroetter综合征急性上肢深静脉血栓,可优先考虑导管导向血栓切除。
  • CAVT可能作为首选技术以减少再干预,但需结合患者具体情况。
  • 术后早期(48小时内)需密切监测再干预需求。

局限性

  • 样本量小(41例),为探索性研究。
  • 单中心回顾性设计,可能存在选择偏倚。
  • 不同技术组样本量不均衡,CAVT组仅17%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Optimal procedural strategies for the management of acute upper extremity deep vein thrombosis (UEDVT) due to Paget-Schroetter syndrome are poorly studied due to its rarity. The aim of this study was to compare short-term patency, complication rates, and course after endovascular therapy of acute UEDVT due to Paget-Schroetter syndrome. METHODS: In this single-center retrospective longitudinal study, data of consecutive patients with acute Paget-Schroetter syndrome treated with interventional thrombectomy at the University Hospital Zurich with any available device: computer assisted vacuum thrombectomy (CAVT), AngioJet/Zelante catheter, or catheter-directed thrombolysis (CDT) was collected. We studied the need for reintervention, primary and secondary patency, and course of symptoms at 2 weeks, 3 months, and 6 months. RESULTS: We included 41 patients with acute UEDVT treated between 2017 and 2025. The median age was 34 years; 61% were men, and 41% were athletes. After a median symptom duration of 4 days, they received thrombectomy with AngioJet/Zelante (61%), CAVT (17%), and CDT (22%). Sixteen patients (39%) required reintervention, mostly within 48 hours (62.5%). Primary patency was 60% (24/40) at 2 weeks, 52.6% (20/38) at 3 months, and 54.1% (20/37) at 6 months (P = .08 for between-group difference). Secondary patency was 72%, 76%, and 86%, respectively. Kaplan-Meier analysis showed higher freedom from reintervention after CAVT (P = .04). Symptom relief occurred mainly within the first 2 weeks: swelling (98% to 17%), pain (60% to 14%). Cyanosis resolved by 6 months, whereas paresthesia slightly increased (15% to 23%). Only one major and one minor bleeding event occurred. CONCLUSIONS: Catheter-directed therapies appeared to be safe and effective for UEDVT due to Paget-Schroetter syndrome. In this exploratory study, bearing the small sample size, the data suggest that single-session thrombectomy (especially CAVT) may be associated with fewer reinterventions and higher primary patency.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Elbaranes N, Ulrich A, Wolf S, et al. Endovascular treatment of acute upper extremity deep vein thrombosis in Paget-Schroetter syndrome: A longitudinal analysis of three endovascular techniques. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 41881255. doi:10.1016/j.jvsv.2026.102485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。